Fusion glycoprotein F0

Fusion glycoprotein F0 Molekülinformation

Englischer NameRespiratory syncytial virus F proteinAnzahl der inverkehr gebrachten Arzneimittel3
Anzahl der klinischen Arzneimittel5Target-AliasProtein F,F,Fusion glycoprotein F0
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameRespiratory syncytial virus F protein
Target-AliasProtein F,F,Fusion glycoprotein F0
Anzahl der inverkehr gebrachten Arzneimittel3
Anzahl der klinischen Arzneimittel5
Höchste Forschungs- und EntwicklungsphaseApproved

Fusion glycoprotein F0 Produktliste

  • Attribut

    Antibody (2)Protein (1)

  • Produktbibliothek

    Online (3)

  • Spezies

    Mouse (2)Mumps virus (1)

  • Etikett

    - (2)His Tag & Avi Tag (1)

  • Marker

    Unconjugated (2)Biotin-labeled (1)

Fusion glycoprotein F0 Molekülhintergrund

The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Fusion glycoprotein F0 Molekülalias

Fusion glycoprotein F0

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology IncRespiratory Syncytial Virus Infections
Details
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences IncRespiratory Syncytial Virus Infections
Details
GR-2102GR2102; GR-2102Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co LtdRespiratory Syncytial Virus Infections
Details
Palivizumab biosimilar (mAbxience)MB-05Phase 1 ClinicalMabxience Sa
Details
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research InstituteRespiratory Syncytial Virus Infections
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, MedImmune Inc, SanofiBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
Details
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections
Details
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01Respiratory Syncytial Virus Infections
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation